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Abstract
Introduction: Inhibitors of the phosphatidylinositol-3-kinase/protein kinase B/mammalian target of rapamycin
(PI3K/AKT/mTOR) pathway can overcome endocrine resistance in estrogen receptor (ER) α-positive breast cancer,
but companion diagnostics indicating PI3K/AKT/mTOR activation and consequently endocrine resistance are lacking.
PIK3CA mutations frequently occur in ERα-positive breast cancer and result in PI3K/AKT/mTOR activation in vitro.
Nevertheless, the prognostic and treatment-predictive value of these mutations in ERα-positive breast cancer is
contradictive. We tested the clinical validity of PIK3CA mutations and other canonic pathway drivers to predict
intrinsic resistance to adjuvant tamoxifen. In addition, we tested the association between these drivers and
downstream activated proteins.
Methods: Primary tumors from 563 ERα-positive postmenopausal patients, randomized between adjuvant tamoxifen
(1 to 3 years) versus observation were recollected. PIK3CA hotspot mutations in exon 9 and exon 20 were assessed with
Sequenom Mass Spectometry. Immunohistochemistry was performed for human epidermal growth factor receptor 2
(HER2), phosphatase and tensin homolog (PTEN), and insulin-like growth factor 1 receptor (IGF-1R). We tested the
association between these molecular alterations and downstream activated proteins (like phospho-protein kinase B
(p-AKT), phospho-mammalian target of rapamycin (p-mTOR), p-ERK1/2, and p-p70S6K). Recurrence-free interval
improvement with tamoxifen versus control was assessed according to the presence or absence of canonic
pathway drivers, by using Cox proportional hazard models, including a test for interaction.
Results: PIK3CA mutations (both exon 9 and exon 20) were associated with low tumor grade. An enrichment of
PIK3CA exon 20 mutations was observed in progesterone receptor- positive tumors. PIK3CA exon 20 mutations
were not associated with downstream-activated proteins. No significant interaction between PIK3CA mutations
or any of the other canonic pathway drivers and tamoxifen-treatment benefit was found.
Conclusion: PIK3CA mutations do not have clinical validity to predict intrinsic resistance to adjuvant tamoxifen
and may therefore be unsuitable as companion diagnostic for PI3K/AKT/mTOR inhibitors in ERα- positive, postmenopausal,
early breast cancer patients.
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Introduction
Recently, inhibitors of the phosphatidylinositol-3-kinase
(PI3K)/AKT/mammalian target of rapamycin (mTOR)
pathway have been introduced into the clinic to over-
come endocrine resistance [1,2]. However, companion
diagnostics for these new targeted drugs are lacking.
Many molecular alterations in this pathway, as well as in
the mitogen-activated protein kinase (MAPK) pathway,
leading to its constitutive activation, have been de-
scribed. Canonic pathway drivers are mutations in the
PIK3CA gene [3], loss of expression or genetic alteration
in the tumor-suppressor gene PTEN [4], and overexpres-
sion of growth factor receptors like human epidermal
growth factor receptor 2 (HER2) and insulin-like growth
factor 1 receptor (IGF-1R) [5].
PIK3CA mutations occur in about 20% to 25% of inva-
sive ductal breast cancers and in approximately 40% of
invasive lobular breast cancers [6], with hotspots in exon
9 (helical domain) and exon 20 (kinase domain). These
mutations have been shown to result in in vitro activa-
tion of the PI3K/AKT/mTOR pathway [3], leading to
endocrine resistance [7]. Nevertheless, the prognostic
and predictive value regarding endocrine resistance of
these mutations in ERα-positive breast cancer remains
unclear. An important limitation of many conflicting
clinical studies [8-12] is the analysis of these mutations
in consecutive series of endocrine-treated patients,
which is unsuitable to discern prognosis from prediction
[13]. Only one previous study [14] analyzed these muta-
tions in the context of a clinical trial that randomized
between adjuvant tamoxifen and control. In this study,
PIK3CA mutations did not predict endocrine resistance,
but were associated with a decreased risk for local recur-
rence. In neoadjuvant endocrine therapy trials, PIK3CA
mutation status was not associated with treatment-induced
Ki67 changes, a surrogate marker for recurrence-free sur-
vival [15], nor with pathologic response [16], whereas the
kinase domain mutations were associated with improved
overall survival. Several other studies have suggested a rela-
tively favorable survival in patients with kinase domain-
mutated breast cancers [8,17], in comparison with patients
without such mutated tumors.
Several other known molecular alterations in the PI3K
and or the MAPK pathway have been studied for their
validity to predict endocrine resistance. Loss of PTEN, a
negative regulator of the PI3K/AKT/mTOR pathway,
frequently occurs in breast cancer [18], but did not have
clinical validity as a single marker in a previous study
[14]. The same holds true for HER2 [19], although the
clinical validity of IGF-1R has not been analyzed in the
context of a randomized clinical trial.
The aim of our study was to investigate the prognostic
and treatment-predictive value of different molecular
alterations in the PI3K and/or MAPK pathways in
postmenopausal breast cancer patients randomized be-
tween adjuvant tamoxifen and no systemic treatment.
In addition, we studied the association between these
molecular alterations and downstream-activated pro-
teins in the PI3K and/or MAPK pathways.
Methods
Patients and material
We recollected primary tumor-tissue blocks from stage I
through III postmenopausal breast cancer patients who
were randomized (2:1) between 1-year tamoxifen (30 mg
per day) and no adjuvant therapy (IKA trial, 1982 to
1994) [20,21]. Study data were part of the Oxford meta-
analysis [22]. After 1989, based on two interim analyses
showing a significant improvement in recurrence-free
survival in lymph node-positive patients, node-positive
patients in this trial skipped the first randomization, and
all received 1 year of tamoxifen. After 1 year, a second
randomization was performed to receive another 2 years
of tamoxifen or to stop further treatment. In total, 1,662
patients were included. None of these patients received
adjuvant chemotherapy. The patient characteristics and
clinical outcome of the original study group (1,662 pa-
tients) were presented elsewhere [21].
Sufficient tumor material was available for 739 patients,
who did not differ in prognostic factors from the total
group (see Additional file 1: Table S1). After revision of
ERα status as assessed with immunohistochemistry (IHC),
a total of 563 ERα-positive tumors were used for subse-
quent analysis. We used a cutoff of ≥ 10% of positive
tumor cells for ERα positivity, because this is a common
practice in The Netherlands and, in addition, this would
avoid the potential inclusion of basal-like tumors [23] in
our analysis. The original trial was approved by the central
ethics committee of the Netherlands Cancer Institute, and
informed consent was obtained from all study partici-
pants. For this retrospective translational study, no
additional consent was required, according to Dutch
legislation [24], because the use of archival pathology
leftover material does not interfere with patient care.
Tumor tissue was handled according to the Dutch
code of conduct for dealing responsibly with human
tissue in the context of health research [25].
Immunohistochemistry
Tissue microarrays (TMAs) were constructed by using
formalin-fixed paraffin-embedded (FFPE) tumor blocks.
A total of three (0.6 mm) cores per tumor were embed-
ded in the TMAs that were stained for ERα, progester-
one receptor (PgR), and HER2. ERα and PgR were
considered positive when ≥10% of invasive cells showed
nuclear reactivity. HER2 was considered positive when
membranous staining was DAKO score 3. In case of a
DAKO score 2, chromogenic in situ hybridization was
Beelen et al. Breast Cancer Research 2014, 16:R13 Page 2 of 10
http://breast-cancer-research.com/content/16/1/R13
performed. For tumors without sufficient cores in the
TMA, whole slides were cut and assessed for ERα (n =
60), PgR (n = 55), and HER2 (n = 36). Tumor grade was
scored on a hematoxylin-eosin-stained slide by using the
modified Bloom-Richardson score [26].
Antibodies used for immunohistochemistry are shown
in Additional file 1: Table S2. Immunohistochemistry for
IGF-1R and PTEN was performed by using the Ventana
Benchmark Ultra system (protocols can be found at
[27]). For IGF-1R, membranous intensity was scored
from 0 to 3. For PTEN protein expression, cytoplasmic
intensity was scored from 0 to 3. The specificity of both
antibodies was tested on a previously described series of
metastatic breast cancer patients [28] for which we had
FFPE material embedded in a TMA, as well as Agilent
44 K mRNA expression data. Results are depicted in
Additional file 1: Figures S1 to S2. Immunohistochemis-
try for downstream phosphorylated (p) proteins in the
PI3K/AKT/mTOR pathway, like p-AKT, p-extracellular
signal-regulated kinase (ERK)1/2, p-mTOR, and p-p70S6K
was performed as previously described [29].
The interobserver variability analyzed by using the
(weighted) Cohen kappa coefficient is depicted in
Additional file 1: Table S3. For further analyses, we
used the scores produced by the first observer (MO).
DNA isolation and PIK3CA mutation analysis
DNA was isolated by using a standard DNA-isolation
protocol, as described in Appendix 1.
PIK3CA mutation status was assessed by using Seque-
nom mass spectrometry–based genotyping technology
for PIK3CA hotspot mutations in exon 9 (E542K and
E545K) and exon 20 (H1047L and H1047R). PCR primers
and extension primers for the various mutations are listed
in Additional file 1: Table S4.
Statistics
The association of PIK3CA mutations, PTEN, HER2,
and IGF-1R protein expression with known clinicopath-
ologic factors was tested by using Fisher Exact tests. The
association with downstream-activated proteins in the
PI3K and/or MAPK pathways was evaluated by using
linear by linear tests. Recurrence-free interval was de-
fined as the time from the date of first randomization
until the occurrence of a local, regional, or distant recur-
rence or breast cancer-specific death. Because a second-
ary contralateral breast tumor cannot be inferred from
the molecular makeup of the primary tumor, whereas
the other types of events can, in relation to tamoxifen
resistance of the primary tumor, this was not considered
an event, and these patients were censored at the date of
their contralateral breast cancer.
We hypothesized that the presence of a molecular al-
teration in the PI3K and/or MAPK pathway is associated
with tamoxifen resistance. In our primary analysis, we
tested the clinical validity of these molecular alterations
as single markers, analyzed as binary factor. Covariate
adjusted Cox proportional hazard regression analyses
were performed, including an interaction variable. The
following molecular alterations were tested: PIK3CA
mutation status (exon 9 mutant versus exon 9 wild-type
and exon 20 mutant versus exon 20 wild-type imputed
as separate factors in one model), HER2 (positive versus
negative), PTEN (negative versus positive), and IGF-1R
(score 3 versus score 0 to 2). In addition, we tested the
interaction with tamoxifen for a composed variable,
defined as any of these molecular alterations present
versus no molecular alteration. Covariates included age
(65 years or older versus younger than 65), grade
(grade 3 versus grades 1 to 2), tumor size (T3 to T4
versus T1 to T2), HER2 status (positive versus nega-
tive), and PgR status (positive versus negative). All sur-
vival analyses were stratified for nodal status. Because
of multiple co-primary end points, the level of signifi-
cance was set at 0.01.
To assess the prognostic value of these molecular al-
terations, we analyzed their putative prognostic potential
by using covariate adjusted Cox proportional-hazard re-
gression analyses in the subgroup of patients who were
randomized to the control arm. We did not use all pa-
tients and corrected for tamoxifen treatment because
this correction would assume that all ERα-positive breast
cancer patients would derive similar benefit from tam-
oxifen. Because the molecular alteration might be associ-
ated with tamoxifen resistance, simply correcting for the
assumed tamoxifen benefit without a correction for a
potential interaction between treatment and molecular
alteration could bias the analysis for prognostic potential.
This study complied with reporting recommendations
for tumor-marker prognostic studies (REMARK) criteria
[30], as outlined in Additional file 1: Table S5.
Results
Associations between molecular alterations in
PI3K/AKT/mTOR pathway and known prognostic
factors and downstream-activated proteins
Genotyping for PIK3CA exon 9 mutations was successful
in 488 ERα-positive tumor samples. Exon 20 mutations
could be assessed in 491 tumor samples (Additional file 1:
Figure S3). In total, 76 tumors harbored a PIK3CA exon 9
mutation (15.6%). Mutations in exon 20 were found in 89
(18.1%) of the tumors. In total, four tumors exhibited
both exon 9 and exon 20 mutations. Overexpression/
amplification of HER2 was seen in 41 (7.7%) of 530 tu-
mors. The frequency of the different hot-spot muta-
tions and the distribution of the intensity of IGF-1R
protein expression are shown in Additional file 1:
Table S6. PTEN protein expression could be assessed
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in 436 tumors, of which 82 (18.8%) did not show ex-
pression of PTEN. When PIK3CA exon 9 and exon 20
were compared with PIK3CA wild-type tumors, mu-
tants were more often low grade. PIK3CA exon 9 mu-
tations were associated with negative HER2 status, and
for PIK3CA exon 20 mutations, an association with
positive progesterone receptor status was observed.
HER2-positive tumors were associated with positive
lymph node status, high grade, and negative PgR status
(Tables 1 and 2). In addition, PTEN-negative tumors were
associated with negative PgR status.
We did not find significant associations between ei-
ther PIK3CA exon 20 mutations or HER2 status and
downstream-activated proteins in the PI3K pathway
(Additional file 1: Table S7). PIK3CA exon 20 muta-
tions were associated with higher p-ERK1/2 levels. Tu-
mors with a PIK3CA exon 9 mutation were associated
with higher p-AKT(Thr308) and p-ERK1/2 expression,
but not with p-mTOR or p-p70S6K. Tumors that were
scored as PTEN-negative had significantly lower levels of
all the downstream-activated proteins than tumors that did
express PTEN. Higher IGF-1R protein expression cor-
related with higher p-AKT (Ser 473) and p-p70S6K
expression. Hierarchic clustering of the different downstream-
activated proteins in the PI3K and/or MAPK pathway is
shown in Figure 1. No clear enrichment appeared for any of
the molecular alterations in tumors that express downstream
activated proteins in the PI3K and/or MAPK pathway.
PIK3CA mutations, loss of PTEN, and overexpression/
amplification of HER2 and/or IGF-1R do not predict
resistance to tamoxifen
Median follow-up of patients without a recurrence event
is 7.8 years. The total number of events in the group of
ERα-positive patients (N = 563) is 132. The number of
patients in each treatment arm before and after interim
analysis is shown in Figure 2. When stratified by nodal
status, the hazard ratio (HR) for tamoxifen versus con-
trol in this cohort was 0.54 (95% confidence interval
(CI), 0.36 to 0.83; P = 0.004). Known prognostic factors
were equally divided over the treatment arms for all
PIK3CA genotypes, with the exception of lymph node status,
which can be explained by the change in randomization
(Additional file 1: Table S8). In our primary analysis, patients
with a tumor with either a PIK3CA exon 9 or exon 20 muta-
tion did not derive significant benefit from tamoxifen (HR,
0.82 (95% CI, 0.22 to 3.04) and 0.77 (95% CI, 0.25 to 2.36),
respectively (Table 3 and Additional file 1: Table S9) How-
ever, the interaction between PIK3CA mutations and tam-
oxifen was not significant. In addition, we did not observe a
significant interaction between any of the other mo-
lecular alterations and tamoxifen, indicating that the
Table 1 Associations between PIK3CA mutation status and clinico-pathologic variables
PIK3CA mutation status
Wild-type Exon 9 mutanta Exon 20 mutanta
n (%) n (%) P valueb n (%) P valueb
Age <65 166 (51) 30 (39) 0.10 39 (44) 0.28
≥65 161 (49) 46 (61) 50 (56)
Lymph node status Negative 177 (54) 39 (51) 0.70 55 (62) 0.23
Positive 150 (46) 37 (49) 34 (38)
T stage T1-2 293 (90) 69 (91) 1.00 79 (89) 0.85
T3-4 34 (10) 7 (9) 10 (11)
Grade Grade 1-2 198 (61) 59 (78) 0.005 65 (73) 0.04
Grade 3 129 (39) 17 (22) 24 (27)
Progesterone receptor Negative 164 (50) 35 (46) 0.70 34 (38) 0.05
Positive 159 (49) 38 (50) 54 (61)
Missing 4 (1) 3 (4) 1 (1)
HER2 Negative 282 (86) 71 (93) 0.03 80 (90) 0.39
Positive 29 (9) 1 (1) 5 (6)
Missing 16 (5) 4 (5) 4 (4)
Histologic subtype Ductal 236 (72) 56 (73) 1.00c 63 (71) 0.84c
Lobular 36 (11) 8 (11) 8 (9)
Other 55 (17) 12 (16) 18 (20)
aA total of four tumors exhibited both exon 9 and exon 20 mutations. bFisher Exact test for mutant versus wild type; only cases without missing values were
analyzed. cFisher Exact test for ductal versus lobular.
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presence or absence of these alterations by itself was
not associated with a significant difference in tamoxi-
fen efficacy in our series (Table 3). In addition, the
composed variable indicating the presence of any of
these molecular alterations did not show a significant
interaction with tamoxifen (Table 3).
PIK3CA mutations have no prognostic effect in patients
randomized to the control arm
In patients who did not receive tamoxifen, we did not
observe an association between either PIK3CA mutation
status, HER2, IGF-1R expression, or PTEN status and
breast cancer prognosis (Table 4).
Table 2 Associations between HER2, PTEN, IGF-1R, and clinico-pathologic variables
HER2 status PTEN IGF-1-R
Negative Positive Negative Positive Low (0–2) High (3)
n (%) n (%) Pvalue n (%) n (%) P value n (%) n (%) P-value
Age <65 233 (48) 18 (44) 0.75 39 (48) 164 (46) 0.90 190 (47) 19 (49) 1.00
≥65 256 (52) 23 (56) 43 (52) 190 (54) 210 (53) 20 (51)
Lymph node status Negative 276 (56) 16 (39) 0.03 42 (51) 189 (53) 0.81 211 (53) 22 (56) 0.74
Positive 213 (44) 25 (61) 40 (49) 165 (47) 189 (47) 17 (44)
T stage T1-2 437 (89) 34 (83) 0.20 70 (85) 317 (89) 0.33 354 (89) 31 (80) 0.12
T3-4 52 (11) 7 (17) 12 (15) 37 (11) 46 (11) 8 (20)
Grade Grade 1-2 342 (70) 9 (22) <0.001 45 (55) 226 (64) 0.16 250 (63) 26 (67) 0.73
Grade 3 147 (30) 32 (78) 37 (45) 128 (36) 150 (37) 13 (33)
Progesterone receptora Negative 222 (45) 30 (73) 0.001 49 (60) 163 (46) 0.03 194 (49) 18 (46) 1.00
Positive 261 (53) 11 (27) 32 (39) 190 (54) 205 (51) 20 (51)
Missing 6 (1) 0 (0) 1 (1) 1 (0) 1 (0) 1 (3)
HER2a Negative 489 (100) 0 (0) na 77 (94) 313 (88) 0.08 357 (89) 36 (92) 0.56
Positive 0 (0) 41 (100) 3 (4) 36 (10) 36 (9) 2 (5)
Missing na na 2 (2) 5 (1) 7 (2) 1 (3)
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Figure 1 Hierarchic clustering of the downstream-activated PI3K and/or MAPK proteins. Heat map representing unsupervised hierarchic clustering
of tumor samples and corresponding downstream activated proteins in the PI3K and/or MAPK pathways from patients for whom the status of
all five proteins was known (N = 350). Patients are represented horizontally. Phosphorylated proteins are indicated vertically. Red represents high/any
expression of phosphorylated protein, and green represents no/low expression of phosphorylated protein (dichotomization was performed according
to the Akaike information criteria [29]). In addition, the presence (red) or absence (green) of different molecular alterations in the PI3K and or MAPK
pathways is shown. (1)Defined as the presence of either a PIK3CA mutation, positive HER2 status, or IGF-1R overexpression (IHC score 3).
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Discussion
Our results indicate that PIK3CA mutations are unlikely
to have important clinical validity to predict adjuvant
tamoxifen resistance in postmenopausal breast cancer
patients. In addition, we have shown that the presence
of a molecular alteration in the PI3K and/or MAPK
pathway is not always associated with high expression of
downstream-activated proteins.
The observed frequency of PIK3CA mutations in the
current study was in line with those reported in the
  Numbers per treatment group pre-interim analysis
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Figure 2 Numbers of patients per randomization group before and after interim analysis. Numbers of patients per randomization group
before interim analysis (A) and after interim analysis (B), for the total subset of 563 ERα-positive patients. From 1989, based on two interim
analyses showing a significant improvement in recurrence-free survival among lymph node-positive patients, these node-positive patients
were all allocated to the tamoxifen treatment arm (that is, skipped the first randomization). Numbers of lymph node-negative patients are
depicted in green. In red are depicted the numbers of lymph node-positive patients. LN neg, lymph node negative; LN pos, lymph node
positive; R1, randomization 1; R2, randomization 2.
Table 3 Adjusted hazard ratios and interaction tests
between PI3K and/or MAPK molecular alterations
and tamoxifen







PIK3CA Wild type 308 0.51 (0.30-0.88)
Exon 20
mutanta
82 0.77 (0.25-2.36) 0.51
Exon 9
mutanta
71 0.82 (0.22-3.04) 0.51
PTEN Negative 78 0.44 (0.15-1.28) 0.63
Positive 348 0.58 (0.34-0.98)
HER2 Negative 479 0.52 (0.33-0.80) 0.52
Positive 41 0.85 (0.19-3.95)
IGF-1R Low (0–2) 390 0.55 (0.33-0.91) 0.90
High (3) 38 0.60 (0.20-1.76)
Any molecular
alteration
Absent 206 0.48 (0.22-1.02) 0.36
Presentb 151 0.76 (0.38-1.53)
aFour tumors exhibited both exon 9 and exon 20 mutations. b Defined as the
presence of either a PIK3CA mutation, negative PTEN status, positive HER 2 status,
or high IGF-1R.
cCovariates included age (≥65 versus <65 years), grade (grade 3 versus grades 1 to
2), tumor size (T3 to T4 versus T1 to T2), HER2 status (positive versus negative), and
progesterone receptor status (positive versus negative).
Table 4 Multivariate hazard ratios according to PI3K and/or






PIK3CA exon 9 mutant
vs PIK3CA wt
111 (28) 0.49 0.11-2.25 0.36
PIK3CA exon 20 mutant
vs PIK3CA wt
111 (28) 0.72 0.24-2.19 0.56
PIK3CA mutant (exon 9
or exon 20) vs PIK3CA wt
111 (28) 0.62 0.25-1.59 0.32
IGF-1R (3 versus 0–2) 96 (27) 1.81 0.67-4.87 0.24
PTEN positive versus
negative
94 (25) 0.97 0.29-3.26 0.96
HER2 positive versus
negative
121 (33) 0.60 0.13-2.76 0.51
aFor each molecular alteration, Cox proportional hazard models were performed
with co-variables: lymph node status, age, tumor size, grade, and progesterone
receptor status. Mt, mutant; wt, wild type.
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literature [8,14,17]. Similar to others [16,31], we ob-
served an association with low tumor grade and negative
HER2 status. Although others did not observe a signifi-
cant association between PIK3CA mutations and tumor
grade [6,8,32], this discordance could be explained by
the relatively small number of patients in these studies.
In the studies from Buttitta [6] and Barbareschi [8], pa-
tients with lobular breast cancer had more often PIK3CA
exon 9 mutated tumors compared with nonlobular breast
cancer. In our study, we did not observe such enrichment
for PIK3CA exon 9 mutations in lobular breast cancer. An
important difference between these studies and our study
population is that we selectively analyzed ERα-positive
postmenopausal breast cancer patients, that are predom-
inantly of low tumor grade. In the other studies [6,8], pa-
tients were younger, and the group of patients with
nonlobular breast cancer included hormone receptor-
negative patients, who are more often high tumor grade,
and are less often PIK3CA-mutated [31]. This might ex-
plain why we observed a higher frequency of PIK3CA
exon 9 mutations in nonlobular breast cancer compared
with the studies from Buttita [6] and Barbareschi [8].
Similar to the results of PIK3CA mutation analysis in al-
most 2,000 patients who participated in the TEAM trial
(treated with adjuvant tamoxifen and/or exemestane) [33],
we observed a positive association between PIK3CA kin-
ase domain mutations and PgR status. Altogether, our
data indicate that in ERα-positive postmenopausal breast
cancer patients, PIK3CA mutations are not enriched in
lobular breast cancer, but are associated with favorable
prognostic factors like low grade and positive PgR status.
In our study, we did not observe an association between
PIK3CA mutations and activation of downstream proteins
like mTOR and p70S6K. Although in vitro data have shown
that PIK3CA mutations result in activation of the PI3K
pathway [3], several studies have now shown that this is
not necessarily the case in the clinical setting [14,34]. Perez
et al. [14] did not find an association between PIK3CA mu-
tations and p-AKT levels, whereas Loi et al. [34] observed
relatively moderate activation of the PI3K pathway in tu-
mors with a PIK3CA exon 20 mutation-associated gene sig-
nature. In addition, in a large series of primary breast
cancers analyzed with exome sequencing and reverse-phase
protein arrays, PI3K pathway activation was not elevated in
PIK3CA-mutated luminal A cancers [35]. One of the expla-
nations for this could be an AKT-independent downstream
signaling in these PIK3CA mutated tumors [36]. Alterna-
tively, relatively moderate pathway activation could be the
result of a feedback mechanism leading to downregulation
secondary to pathway activation. Previously it was shown
that a negative-feedback loop between mTOR/p70S6K and
the IRS protein results in a reduction of the IRS protein in
response to activation of mTOR/p70S6K, with subsequent
inhibition of the PI3K pathway [37].
In contrast, IGF-1R protein expression was signifi-
cantly associated with p-p70S6K. Elevated IGF-1R sig-
naling has been shown to result in activation of the PI3K
and MAPK pathways in vitro [38]. Surprisingly, in tu-
mors that scored negative for PTEN, we observed rela-
tively low expression of downstream-activated proteins
in the PI3K pathway. Although the robustness of PTEN
antibodies has been a matter of debate, the reliability of
the PTEN antibody we used was previously shown [39].
In addition, we showed a significant association between
PTEN immunoscoring and mRNA expression. Similar to
our results, Perez et al. [14] observed relatively low ex-
pression of AKT in patients whose tumor was negative
for PTEN. The underlying mechanism for this unex-
pected observation remains unclear. An explanation
could be that activation of the PI3K pathway in tumors
that lack PTEN is relatively low compared with tumors
that exhibit PI3K pathway activation from other causes.
In patients randomized to the control arm, we did not
observe an association between PIK3CA mutations, or
any of the other tested molecular aberrations, and breast
cancer prognosis, when corrected for known prognostic
factors, such as the PgR status and histologic tumor
grade. The relatively low number of HER2-positive
breast cancer patients in this series may explain the ab-
sence of a significant association between HER2 overex-
pression and breast cancer prognosis. It is well known
that the incidence of HER2 overexpression in the
Netherlands is lower than that observed in other coun-
tries [40]. With respect to the association of IGF-1R with
breast cancer outcome, discordant results have been
published [41-45]. These conflicting results may be ex-
plained by heterogeneous patient populations (like dif-
ference in histologic subtype and treatment) as well as
differences in antibodies used.
The association between PIK3CA mutation and breast
cancer prognosis has been controversial [31]. Previously,
a PIK3CA exon 20 gene signature was associated with
favorable outcome in both tamoxifen-treated patients
and in patients who did not receive adjuvant systemic
treatment [34]. PIK3CA mutation status, as defined with
sequencing, did not have prognostic value in this study.
Several other studies have suggested a favorable progno-
sis in patients harboring PIK3CA mutations [8,14]. A
preliminary analysis of PIK3CA mutations in patients
participating in the TEAM trial did not find a significant
association with outcome [33]. In a recent meta-analysis
showing a favorable clinical outcome in ERα-positive
postmenopausal breast cancer patients with PIK3CA
kinase domain mutations, a potential favorable response
to endocrine treatment was suggested as one of the ex-
planations [46]. Our results indicate that this is not likely
to be true. A potential bias of these cohort studies is that
the prognostic value of PIK3CA mutations is analyzed in
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breast cancer patients who all received adjuvant endo-
crine therapy. The prognosis of patients with PIK3CA
mutations who have been treated with endocrine therapy
is determined by both tumor biology and treatment ef-
fect, where the latter can range from substantial to no
treatment effect. Hence its tumor biologic prognostic
value cannot be deduced from such a study design.
The observed absence of a significant interaction between
PIK3CA hotspot mutations and tamoxifen-treatment bene-
fit in our study does not rule out a potential reduced effect
of tamoxifen in patients carrying these hotspot mutations.
Moreover, we cannot exclude that the benefit of tamoxifen
might be reduced in patients whose tumors express a rare
mutation in the PIK3CA gene or other genes in the PI3K/
AKT/mTOR pathway (like AKT1 mutations). Considering
their relatively low prevalence [35], we did not determine
these mutations, because the power of this study to demon-
strate an interaction between these mutations, analyzed as
single markers, and tamoxifen treatment is low. For similar
reasons, we cannot exclude a potential reduced benefit
from tamoxifen in patients whose tumors exhibit one of
the canonic pathway drivers, like loss of PTEN and overex-
pression of HER2 and/or IGF-1R. Nevertheless, when a
composed variable was tested, indicating the presence of
any of these molecular alterations, again no significant
interaction was found. We do not expect that the addition
of other (rare) mutations in these analyses would substan-
tially change these results.
In contrast, analysis of p-p70S6K identified a similar
amount of patients and showed a highly significant test
for interaction [29]. In PIK3CA-mutated tumors that do
express p-p70S6K, a reduced effect is likely, but cannot be
demonstrated because of lack of power. A meta-analysis
of these markers on tumor material available from ran-
domized clinical trials of adjuvant tamoxifen versus nil
(for example, NSABP B-14 trial [47], NATO and CRC ad-
juvant breast trials [48,49], and the Stockholm trial [50])
might generate more definitive answers regarding these
biomarkers.
Considering our observations in ERα-positive early
breast cancer patients, it is not likely that PIK3CA hotspot
mutation status by itself would be a suitable companion
diagnostic predicting benefit from the putative use of
PI3K/AKT/mTOR inhibitors in the adjuvant setting.
Phase I data have shown a higher response rate for pa-
tients with gynecologic malignancies carrying a PIK3CA
mutation treated with PI3K/AKT/mTOR inhibitors com-
pared with patients with wild-type tumors [51]. However,
whether this is also true for ERα-positive breast cancer
must be defined in prospective randomized clinical trials,
both in the metastatic and adjuvant settings, with these
novel targeted agents. Our data indicate that the selection
of patients for these trials should not be restricted to
PIK3CA hotspot mutation carriers only.
Conclusion
Novel targeted agents inhibiting the PI3K/AKT/mTOR
pathway have a promising role in the treatment of patients
with hormone receptor-positive breast cancer resistant to
anti-estrogens as single agent. Because PIK3CA hotspot
mutations frequently occur and are known to activate the
PI3K/AKT/mTOR pathway, these mutations are generally
considered a potential predictive biomarker. Our observa-
tions indicate that PIK3CA hotspot mutations have lim-
ited potential to predict intrinsic tamoxifen resistance in
the adjuvant treatment of ERα-positive, postmenopausal
breast cancer patients. Furthermore, no clear association
between these mutations and activation of downstream
proteins in the PI3K/AKT/mTOR pathway has been
found in these patients. For identification of companion
diagnostics, the focus should switch to the analysis of acti-
vated proteins downstream in the PI3K/AKT/mTOR
pathway, which are associated with adjuvant tamoxifen re-
sistance [29].
Appendix 1
From paraffin-embedded tissue blocks, 10-μm-thick sec-
tions were cut and attached to microscope slides. In
total, 10 slides per tumor were used for DNA isolation.
Slides were deparaffinized in xylene, rehydrated, and
stained with hematoxylin. The slides were incubated
with sodium thiocyanate overnight. Exact tumor location
was circled by a pathologist on an HE-stained slide,
which was used as a template. After adding a drop of tis-
sue lysis buffer, tumor tissue was scraped from the
slides, added to a 1.5-μl micro centrifuge tube contain-
ing a 200-μl mix of tissue lysis buffer/proteinase K. This
tube was incubated in a thermomixer at 55°C for 48
hours. An additional 27 μl proteinase K (2 mg/μl) was
added after 24 and 36 hours. After 48 hours, the tube
was incubated at 80°C for 10 minutes to inactivate pro-
teinase K. After centrifuging, the supernatant was pipet-
ted into a new tube. DNA was purified by using a
QIAquick PCR purification kit.
Additional file
Additional file 1: Table S1. Distribution of clinicopathologic variables
between patients with sufficient tumor material for biomarker analysis
and the total group of patients who entered the study. Table S2.
Antibodies used for immunohistochemical assays. Table S3. Interobserver
variability. Table S4. PIK3CA primers for MassARRAY. Table S5.
Specifications of REMARK recommendations. Table S6. Frequencies of
specific PIK3CA mutations in exon 9 (A), exon 20 (B), and the distribution
of and IGF-1R protein expression intensity (C). Table S7. Associations
between PI3K/AKT/mTOR molecular alterations (columns) and downstream
activated proteins (rows). Depicted are the P values for linear by linear tests.
Table S8. Patient characteristics by treatment arm and PIK3CA mutation
status. Table S9. Multivariate Cox proportional hazard model of
recurrence-free interval (RFI) including PIK3CA mutation status and
interaction with tamoxifen treatment. Figure S1. Membranous IGF-1R
protein expression according to immunohistochemical staining of
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TMA cores from primary breast cancers compared with mRNA levels
that were available from hybridization to a 44-K oligoarray (Agilent
Technologies). In total, 40 cases of 69 patients were evaluable for IHC.
In total, six IGF-1R probes were available, showing all similar results.
The figure shows the data for the first IGF-1R probe (A_23_P205986).
Linear-by-linear test was performed by using IGF-1R mRNA levels split
by quartiles. Figure S2. Cytoplasmic PTEN protein expression according
to immunohistochemical staining of TMA cores from primary breast cancers
compared with mRNA levels that were available from hybridization to a 44K
oligoarray (Agilent Technologies). In total, 36 cases of 69 patients were
evaluable for IHC. In total, three PTEN probes were available, showing
all similar results. The figure shows the data for the first PTEN probe
(A_23_P98085). Figure S3. Data flow.
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